Pain is no longer just a symptom, it's a specialty. And in 2025, the Interventional Pain Management (IPM) field is showing powerful momentum both clinically and commercially.

According to a recent Coherent Market Insights report, the IPM market is valued at $73.2 billion in 2025, projected to grow to $108.5 billion by 2032 at a 6.5% CAGR. This growth is not just about numbers, it reflects a fundamental shift in how chronic pain is being diagnosed, managed, and monetized.

What’s Fueling the Growth?

1. Aging Population, Rising Pain Cases
   With the global elderly population climbing steadily, pain physicians are seeing a predictable rise in referrals for conditions like lumbar radiculopathy, spinal stenosis, and facet arthropathy.

2. Shift Away from Opioids
   The regulatory and payer environment continues to support non-opioid interventions. Radiofrequency ablation, spinal cord stimulation, and other image-guided procedures are becoming standard-of-care for patients and reimbursement is following.

3. Technology Driving Precision
   Advances in neurostimulation, regenerative therapies, and imaging tech allow for safer, more targeted interventions. For physicians, this means shorter recovery times and improved outcomes. For investors, it signals a product-driven growth model.

4. ASC-Centric Practice Models
   Procedures are moving from hospitals to outpatient settings, with ASCs and OBLs (Office-Based Labs) now performing a substantial share of spine and pain procedures. This reduces cost, improves throughput, and opens up new investment avenues.

What This Means for Pain Physicians

If you're in practice, this is the moment to:

• Evaluate your procedure mix – Are you underutilizing RFA or SCS?

• Explore partnerships – Consolidators and ASC platforms are actively seeking regional pain leaders.

• Stay ahead of compliance and outcome reporting – Especially if you’re considering growth, M&A, or raising capital.

What This Means for Investors

Pain management is becoming one of the most defensible niches in outpatient care:

• Recurrent revenue from ongoing patient care

• Scalable platforms for private equity roll-ups

• Tech-centric upside through devices, biologics, and AI in diagnostics

The key is identifying physician-led platforms with strong compliance, ASC access, and consistent procedural outcomes.

Final Takeaway

In 2025, Interventional Pain Management isn’t just expanding, it’s maturing into a high-growth, high-impact sector.
For physicians, that means more tools and more autonomy.
For investors, it means durable demand and recession-resistant returns.